Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety.

@article{Geller2007NovelTI,
  title={Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety.},
  author={David E. Geller and Michael W Konstan and Jeffrey Smith and Sarah B. Noonberg and Carol Conrad},
  journal={Pediatric pulmonology},
  year={2007},
  volume={42 4},
  pages={307-13}
}
Aerosolized antibiotics are associated with a high treatment burden that can result in non-adherence to chronic therapy. We evaluated the pharmacokinetics (PK) and safety of tobramycin inhalation powder (TIP), a novel dry-powder formulation designed to deliver a high payload of tobramycin topically to the lungs for management of chronic Pseudomonas aeruginosa infections. This was a multi-center, open-label, sequential-cohort, single-dose, dose-escalation study using the standard 300 mg dose of… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 80 extracted citations

Inhaled formulations and pulmonary drug delivery systems for respiratory infections.

Advanced drug delivery reviews • 2015
View 4 Excerpts
Highly Influenced

Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society • 2009
View 4 Excerpts
Highly Influenced

Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society • 2009
View 3 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…